NP-G2-044 Monotherapy, Anti-PD-1 Therapy, NP-G2-044 Combination therapy — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-30 in 8d
ESTIMATED |
READOUT
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Me
Phase 1/2 · Advanced or Metastatic Solid Tumor Malignancies |
Novita Pharmaceuticals, Inc. | NP-G2-044 Monotherapy, Anti-PD-1 Therapy |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|